• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·PFE
Held by 3 Gurus
Share

Pfizer Inc. Stocks

$ 26.04Last Updated 16.06.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 149.38B

$ 26.04
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Manager
Fund
Portfolio Weight (%)
Change
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Sign up, to see portfolios that hold this stock
Sign up, to see portfolios that hold this stock

Latest news

06.02.2026 15:00

Agomab Therapeutics IPO: Pfizer and Sanofi-backed biotech starts trading

04.02.2026 15:45

Morning in New York: investors in search of a foothold

03.02.2026 22:30

Pfizer reveals data on obesity drug. Why are analysts and the market disappointed?

17.12.2025 15:10

Morning in New York: foreign policy news is the market's focus

16.12.2025 20:50

Pfizer expects performance to fall due to lower sales of Covid vaccines. Shares fall

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Pfizer Inc. operates as a global biopharmaceutical enterprise, actively involved in the discovery, innovation, manufacturing, promotion, distribution, and sale of its pharmaceutical portfolio across the United States, Europe, and numerous international markets. The company’s comprehensive product range encompasses medicines and vaccines for a wide spectrum of therapeutic areas. These include treatments for cardiovascular and metabolic conditions, migraines, and women's health, exemplified by brands such as Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family. Pfizer also addresses infectious diseases with products like the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba, alongside its contributions to COVID-19 prevention and treatment, featuring Comirnaty and Paxlovid, and ongoing efforts in mRNA and antiviral technologies. Further offerings include biosimilars for chronic immune and inflammatory disorders, represented by Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo; and specialized medications for conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease, found under brands like the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin. The company also supplies sterile injectable and anti-infective medications, including Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga, in addition to a substantial oncology and specialty pipeline featuring biologics, small molecules, immunotherapies, and biosimilars like Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi. Additionally, Pfizer engages in contract manufacturing services. Its clientele is diverse, spanning wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical offices, and integrated healthcare delivery systems. The company maintains significant collaboration agreements with partners such as Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE. Pfizer Inc. was established in 1849 and has its corporate headquarters situated in New York, New York.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, reasonably priced

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of PFE is 27 and suggests 4.65% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.06.2026 17:54

Trump threatened Iran with new strikes if "he doesn't like the deal"

17.06.2026 17:50

Analysts have identified a rare beneficiary of the growing demand for GLP-1 from the food industry

17.06.2026 17:25

Anthropic is preparing for an IPO. 4 small-cap stocks that could benefit from this

17.06.2026 16:55

Bets on a stronger U.S. dollar have risen at the fastest pace in eight years

17.06.2026 16:10

The Nvidia CEO's Favorite, Backed by Milner: What Makes the Startup Acquired by SpaceX So Notable?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026